Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | CTSA | P10619 | 3/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510648 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP | |
| SCHEMBL27347770 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP | |
| SCHEMBL20545820 | 0.91 | CTSA (0.56) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP | |
| SCHEMBL20545819 | 0.91 | CTSA (0.56) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP | |
| SCHEMBL20546802 | 0.88 | KMT2A (0.54) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP | |
| SCHEMBL20546800 | 0.88 | KMT2A (0.54) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP | |
| SCHEMBL14432240 | 0.86 | PARP1 (0.46) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP | |
| Hydrochloric Acid SCHEMBL20546996 | 0.85 | KMT2A (0.59) | KMT2ASMN1; SMN2CYP26A1L3MBTL1FFAR1 | |
| Hydrochloric Acid SCHEMBL20546995 | 0.85 | KMT2A (0.59) | KMT2ASMN1; SMN2CYP26A1L3MBTL1FFAR1 | |
| SCHEMBL4931341 | 0.83 | SLC6A9 (0.45) | KMT2ASMN1; SMN2CYP26A1ANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023624-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3699162-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | CITIZENS BANK, N.A. | 2021-08-12 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3335736-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10647666-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10640461-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190276393-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| EP-2942065-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | disclosed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | UBE INDUSTRIES, LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1621529-A1 | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | Ube Industries, Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-20040116353-A1 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI (FR) | 2004-06-17 | — | — | US | disclosed |
| US-6667334-B1 | Inhibitors of adhesion and migration of leukocytes and/or antagonists of adhesion receptor VLA-4 belonging to integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-23 | — | — | US | disclosed |
| EP-1077994-A1 | IMIDAZOLIDINE DERIVATIVES, THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999060015-A1 | IMIDAZOLIDINE DERIVATIVES, THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | KMT2A 2413/4885SMN1; SMN2 3022/4885CYP26A1 1134/4885 |
| US-20190276393-A1 | Heterodimers of Glutamic Acid | GLUL, DDO, ASNS | KMT2A 2234/4885SMN1; SMN2 2996/4885CYP26A1 1528/4885 |
| US-10647666-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | KMT2A 2413/4885SMN1; SMN2 3022/4885CYP26A1 1134/4885 |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | ALAD, ARSA, ALDH7A1 | KMT2A 4127/4885SMN1; SMN2 3856/4885CYP26A1 94/4885 |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | KMT2A 2402/4885SMN1; SMN2 2993/4885CYP26A1 1150/4885 |
| US-10640461-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | KMT2A 2413/4885SMN1; SMN2 3022/4885CYP26A1 1134/4885 |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | KMT2A 2413/4885SMN1; SMN2 3022/4885CYP26A1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.